Recent Updates
Recently added Catalysts
BAX Positive Sentiment

Baxter Appoints John Rogers Chief Financial Officer

Wednesday, August 19, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Baxter International Inc. has appointed John Rogers as the new Chief Financial Officer, effective October 1, 2026. Rogers, who will report to CEO Andrew Hider, is recognized for his global finance experience and success in leading transformation initiatives. This appointment is expected to enhance Baxter's financial leadership.

Market Sentiment Analysis

POSITIVE FACTORS

  • John Rogers has extensive operational expertise.
  • He has a successful track record in transformation initiatives.
  • His appointment is seen as a strategic move for Baxter.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+18%
120-day peak, hindsight
Typical move
1.9%
average across 12 past catalysts
Lead asset
Dianeal
Phase 3 · End Stage Renal Disease (ESRD)

Full Press Release Details

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as executive vice president and chief financial officer (CFO), reporting to Baxter president and chief executive officer (CEO), Andrew Hider, effective Oct. 1, 2026. “John is a proven global finance executive with extensive operational expertise and a successful track record leading complex transformation initiatives,” said Hider. “He is an ideal fit for

Frequently Asked Questions

Who is the new CFO of Baxter?

John Rogers has been appointed as the new Chief Financial Officer of Baxter.

When will John Rogers start as CFO?

John Rogers will officially start as CFO on October 1, 2026.

Who does John Rogers report to at Baxter?

John Rogers will report to Andrew Hider, the president and CEO of Baxter.

What is John Rogers known for?

He is known for his extensive operational expertise and successful transformation initiatives.

ShareAdd on Google
Tags: BAX Viatris Investor Conferences Healthcare Baxter International John Rogers CFO financial leadership medtech
Last updated: Aug 19, 2026

Biotech snapshot

Cash runway
$2151M liquidity · $0M/mo burn
Low dilution risk
Lead asset
DianealPhase 3
End Stage Renal Disease (ESRD) →

Catalyst track record

+18%
best trade around BAX's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for BAX.

See every catalyst's timing & PoA →